Morepen Laboratories Enters US Prescription Generics Market with Desloratadine Launch

Indian pharmaceutical company Morepen Laboratories Limited has entered the United States prescription generic medicines market with the launch of Desloratadine Tablets USP, 5 mg, marking an important expansion of its international pharmaceutical business. Announced on 9 November 2026, the development represents the company’s progression from supplying active pharmaceutical ingredients (APIs) to participating directly in the development and distribution of finished prescription medicines in one of the world’s largest pharmaceutical markets.

The new product will be distributed through Morepen Bio Inc., the company’s wholly owned US subsidiary, in packs containing 100 and 500 tablets. The launch builds upon Morepen’s longstanding experience in manufacturing and supplying Desloratadine API to American pharmaceutical customers and forms part of its broader strategy to develop an integrated, research-driven pharmaceutical business.

Desloratadine Marks Entry into US Prescription Generics

Desloratadine is a second-generation antihistamine used to treat allergic conditions, including seasonal and perennial allergic rhinitis. It helps relieve symptoms such as sneezing, runny nose, nasal itching and other allergy-related discomfort.

Morepen Laboratories has supplied the active pharmaceutical ingredient used in Desloratadine formulations to the United States for several years. The latest launch enables the company to expand its participation in the pharmaceutical value chain by moving into finished-dosage medicines and commercial distribution.

The Desloratadine Tablets USP, 5 mg, will be introduced through Morepen Bio Inc., allowing the company’s American subsidiary to develop its presence in the prescription generic medicines segment.

The launch represents a new commercial direction for Morepen’s international operations, extending its business beyond traditional API exports into pharmaceutical formulations intended for regulated markets.

Building on India’s Pharmaceutical Manufacturing Capabilities

India has established a substantial international presence in the manufacturing and export of generic medicines and pharmaceutical ingredients. Indian pharmaceutical companies supply affordable medicines to markets worldwide, supported by manufacturing expertise, formulation development capabilities and experience working within international regulatory frameworks.

Morepen’s latest expansion illustrates how Indian manufacturers are increasingly seeking opportunities further along the pharmaceutical value chain.

API production involves manufacturing the active chemical substances responsible for the therapeutic effects of medicines. Finished-dosage manufacturing requires additional capabilities in formulation development, product testing, pharmaceutical quality systems, packaging and regulatory compliance.

By expanding into prescription generic products, Morepen aims to combine its established API manufacturing business with formulation development and international distribution capabilities.

This approach can provide greater opportunities for value addition while allowing Indian pharmaceutical manufacturers to participate more extensively in international healthcare supply chains.

US Subsidiary to Lead Prescription Medicines Distribution

Morepen Bio Inc. will serve as the company’s distribution platform for its new prescription generic product in the United States.

The subsidiary supports Morepen’s pharmaceutical commercialisation activities in the American market, encompassing prescription medicines, over-the-counter healthcare products and related pharmaceutical business development.

Morepen has previously introduced over-the-counter products in the United States. The Desloratadine launch therefore represents an expansion into prescription generics rather than the company’s first entry into the American pharmaceutical market.

The distinction is significant because prescription generic medicines operate within a specialised regulatory and commercial framework involving approved pharmaceutical products, healthcare providers, pharmacies and distribution networks.

Morepen intends to use its existing relationships with pharmaceutical customers and its experience supplying APIs to support the development of its prescription medicines business.

Morepen Files First USFDA Application for Sitagliptin Tablets

Alongside the Desloratadine launch, Morepen Laboratories has confirmed the submission of its first Abbreviated New Drug Application (ANDA) to the United States Food and Drug Administration.

The application concerns Sitagliptin Phosphate Tablets USP in three strengths: 25 mg, 50 mg and 100 mg.

Sitagliptin is an oral antidiabetic medicine used to improve blood glucose control in adults with type 2 diabetes. The drug belongs to the dipeptidyl peptidase-4 inhibitor class, which works by supporting the body’s regulation of insulin and glucose metabolism.

An Abbreviated New Drug Application is the regulatory pathway used by manufacturers seeking approval to market generic versions of eligible medicines in the United States.

The process requires pharmaceutical companies to demonstrate that their proposed generic products meet applicable requirements for pharmaceutical quality, safety and therapeutic equivalence.

Morepen’s Sitagliptin application is currently under regulatory review. The company has not announced USFDA approval or commercial launch of this product.

The filing nevertheless represents an important development in Morepen’s formulation research, analytical capabilities and international regulatory operations.

Expanding Research and Contract Manufacturing Capabilities

Morepen’s expansion into prescription generics forms part of a broader strategy combining active pharmaceutical ingredients, finished formulations and contract development and manufacturing services.

The company’s Contract Development and Manufacturing Organisation business provides pharmaceutical development and manufacturing services to external customers.

These activities can encompass formulation research, process development, analytical testing and commercial manufacturing, allowing pharmaceutical companies to use specialised external manufacturing capabilities.

Morepen has been expanding its CDMO activities while seeking to strengthen its presence in regulated pharmaceutical markets.

The integration of API manufacturing, formulation development and contract manufacturing creates opportunities for the company to participate in multiple stages of pharmaceutical product development.

The US prescription generic launch complements this strategy by adding a commercial distribution component to its existing industrial and research capabilities.

Company Plans Additional US Generic Medicine Filings

Morepen Laboratories has indicated that it intends to pursue additional prescription generic filings and distribution opportunities in the United States.

The company plans to focus on products where its established API manufacturing expertise and pharmaceutical research capabilities provide a foundation for expansion.

Its future strategy also includes evaluating selected opportunities involving high-potency active pharmaceutical ingredients and oncology-related products.

High-potency APIs are used in specialised medicines that require advanced manufacturing controls, containment systems and technical expertise because of their biological activity.

Oncology represents another important area of pharmaceutical development, involving medicines used in cancer treatment.

The company has described these segments as potential future opportunities rather than confirmed product launches or approved manufacturing projects.

The expansion of its prescription generic portfolio will allow Morepen to build upon its regulatory experience and strengthen its participation in international pharmaceutical markets.

Strengthening India’s Presence in Regulated Pharmaceutical Markets

The United States represents an important market for Indian pharmaceutical manufacturers because of its substantial demand for generic medicines and its established regulatory framework.

Indian companies have developed considerable expertise in supplying both active pharmaceutical ingredients and finished formulations to American healthcare markets.

Morepen’s progression into prescription generic medicines reflects the increasing capabilities of Indian pharmaceutical businesses in formulation development, regulatory submissions and international commercial operations.

The company’s longstanding Desloratadine API business provides an existing technical foundation for its expansion into finished products.

Its parallel Sitagliptin regulatory application also demonstrates the development of additional capabilities in formulation research and pharmaceutical regulatory documentation.

These activities support the broader evolution of India’s pharmaceutical industry towards higher-value manufacturing, specialised product development and direct participation in international medicine supply chains.

A New Phase in Morepen’s International Expansion

Morepen Laboratories’ launch of Desloratadine Tablets USP, 5 mg, in the United States represents an important milestone in the company’s pharmaceutical development strategy.

The introduction of its first US prescription generic product enables Morepen to move beyond supplying pharmaceutical ingredients and participate directly in the distribution of finished medicines through its American subsidiary.

The development also complements its expanding CDMO business and regulatory pipeline, including its first USFDA application for Sitagliptin tablets.

By combining established API manufacturing capabilities with formulation development, regulatory expertise and international distribution, Morepen is strengthening its position as an integrated Indian pharmaceutical enterprise.

The company’s expansion illustrates the growing ambition of Indian pharmaceutical manufacturers to increase value addition, develop specialised products and establish a stronger presence across global pharmaceutical markets.

---